[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"levothyroxine\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:levothyroxine":69},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":13,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100565855",false,"NCT06647602","Thyroid Hormone Replacement After Radio Iodine: Value and Efficacy","THRIVE","Inclusion Criteria:\n\n* Histologically confirmed DTC (papillary thyroid carcinoma, follicular thyroid carcinoma, oncocytic thyroid carcinoma)\n* Classified as high-risk DTC according to the ATA guidelines or, patients for whom the risk of a recurrence is estimated to be higher based on clinical features (assessed by their treating physician).\n* Prepared for RAI-therapy with TH-withdrawal\n* Patients must be fit to adhere to the study protocol\n* Patients must be able to read and understand the Dutch language\n\nExclusion Criteria:\n\n* Pregnancy\n* Patients with comorbidities, such as severe heart failure, (poorly controlled) atrial fibrillation, of which the treating physician decides that L-T3 is unsuitable.\n* Conditions or drugs interfering with thyroid hormone uptake:\n* Patients with a history of atrophic gastritis\n* Patients using proton-pomp inhibitors","ALL","18 Years","75 Years",{"count":19,"type":20},40,"ESTIMATED","OBSERVATIONAL","This study will be a multicentre prospective cohort study on TH-substitution after thyroid hormone withdrawal preceding radioiodine treatment.",[24,25,26,27,28],"Differentiated Thyroid Cancer","Thyroid Cancer","Levothyroxine","Liothyronine","Thyroid Hormones","NOT_YET_RECRUITING","2026-02-05",{"date":32,"type":33},"2026-02-10","ACTUAL",{"date":35,"type":20},"2026-09-01",{"date":37,"type":20},"2028-12-31",{"name":39,"class":40},"University Medical Center Groningen","OTHER",{"id":42,"slug":4,"hasResults":10,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":10,"sex":15,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":68},"100623171","NCT07393165","Levothyroxine Treatment on Cardiac Function in Children With Subclinical Hypothyroidism","The Effect of Levothyroxine Treatment on Cardiac Function in Children With Subclinical Hypothyroidism","Inclusion Criteria:\n\n* Age from 4 to 15 years.\n* Both sexes.\n* Patients with stable elevated thyroid-stimulating hormone (TSH) ≥ 4.5 mIU\u002FL with normal free T4 and ft3 in different measurement 4 - 6 weeks apart.\n\nExclusion Criteria:\n\n* Overweight and obesity\n* Hypertension\n* Previous use of levothyroxine, antiepileptic drugs, or cardiac drugs within the last 6 months.\n* Arrhythmia.\n* Congenital or acquired heart disease\n* Liver or kidney disease\n* Hyperlipidemia\n* Diabetes\n* Infectious diseases\n* Respiratory diseases\n* Malignancies","4 Years","15 Years",{"count":19,"type":20},"INTERVENTIONAL",[52],"NA","This study aims to evaluate the effect of the treatment with levothyroxine on cardiac function in children with subclinical hypothyroidism.",[26,55,56,57],"Cardiac Function","Children","Subclinical Hypothyroidism","RECRUITING","2026-01-31",{"date":61,"type":33},"2026-02-06",{"date":63,"type":33},"2025-05-24",{"date":65,"type":20},"2026-05-01",{"name":67,"class":40},"Tanta University",1,""]